메뉴 건너뛰기




Volumn 26, Issue 2, 2008, Pages 141-146

Antibody therapy in renal cell carcinoma

Author keywords

CAIX; G250; Monoclonal antibody; RCC; Renal; Therapy; VEGF

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

EID: 42349116479     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0236-5     Document Type: Article
Times cited : (5)

References (33)
  • 2
    • 0016756272 scopus 로고
    • Continuous cultures of fused cells secreting antibody of predefined specificity
    • Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497
    • (1975) Nature , vol.256 , Issue.5517 , pp. 495-497
    • Kohler, G.1    Milstein, C.2
  • 3
    • 2942591945 scopus 로고    scopus 로고
    • The cancer/testis genes: Review, standardization, and commentary
    • Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 4:1
    • (2004) Cancer Immun , vol.4 , pp. 1
    • Scanlan, M.J.1    Simpson, A.J.2    Old, L.J.3
  • 4
    • 0022502868 scopus 로고
    • Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney
    • Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J et al (1986) Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38(4):489-494
    • (1986) Int J Cancer , vol.38 , Issue.4 , pp. 489-494
    • Oosterwijk, E.1    Ruiter, D.J.2    Hoedemaeker, P.J.3    Pauwels, E.K.4    Jonas, U.5    Zwartendijk, J.6
  • 6
    • 0024378807 scopus 로고
    • Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas
    • Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr, Whitmore WF Jr et al (1989) Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer Res 49(23):6774-6780
    • (1989) Cancer Res , vol.49 , Issue.23 , pp. 6774-6780
    • Bander, N.H.1    Finstad, C.L.2    Cordon-Cardo, C.3    Ramsawak, R.D.4    Vaughan Jr., E.D.5    Whitmore Jr., W.F.6
  • 7
    • 0022353525 scopus 로고
    • Monoclonal antibodies to human renal cell carcinoma: Recognition of shared and restricted tissue antigens
    • Vessella RL, Moon TD, Chiou RK, Nowak JA, Arfman EW, Palme DF et al (1985) Monoclonal antibodies to human renal cell carcinoma: Recognition of shared and restricted tissue antigens. Cancer Res 45(12 Pt 1):6131-6139
    • (1985) Cancer Res , vol.45 , Issue.12 PART 1 , pp. 6131-6139
    • Vessella, R.L.1    Moon, T.D.2    Chiou, R.K.3    Nowak, J.A.4    Arfman, E.W.5    Palme, D.F.6
  • 8
    • 0022532574 scopus 로고
    • Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma
    • Oosterwijk E, Ruiter DJ, Wakka JC, Huiskens-van der Meij JW, Jonas U, Fleuren GJ et al (1986) Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma. Am J Pathol 123(2):301-309
    • (1986) Am J Pathol , vol.123 , Issue.2 , pp. 301-309
    • Oosterwijk, E.1    Ruiter, D.J.2    Wakka, J.C.3    Huiskens-van der Meij, J.W.4    Jonas, U.5    Fleuren, G.J.6
  • 9
    • 0028897420 scopus 로고
    • Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis
    • Gnarra JR, Lerman MI, Zbar B, Linehan WM (1995) Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22(1):3-8
    • (1995) Semin Oncol , vol.22 , Issue.1 , pp. 3-8
    • Gnarra, J.R.1    Lerman, M.I.2    Zbar, B.3    Linehan, W.M.4
  • 10
    • 0030856731 scopus 로고    scopus 로고
    • Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
    • Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20):4593-4599
    • (1997) Cancer Res , vol.57 , Issue.20 , pp. 4593-4599
    • Presta, L.G.1    Chen, H.2    O'Connor, S.J.3    Chisholm, V.4    Meng, Y.G.5    Krummen, L.6
  • 11
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307(5706):58-62
    • (2005) Science , vol.307 , Issue.5706 , pp. 58-62
    • Jain, R.K.1
  • 12
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427-434
    • (2003) N Engl J Med , vol.349 , Issue.5 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3    Hwu, P.4    Schwartzentruber, D.J.5    Topalian, S.L.6
  • 13
    • 35549006672 scopus 로고    scopus 로고
    • A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma
    • (June Supplement)
    • Escudier B, Koralewski A, Pluzanska A, Ravaud S, Bracarda C, Szczylik C et al. (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol, 2007 ASCO annual meeting proceedings part 1, vol 25, no 18S (June Supplement):3
    • (2007) J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part 1 , vol.25 , Issue.18 S , pp. 3
    • Escudier, B.1    Koralewski, A.2    Pluzanska, A.3    Ravaud, S.4    Bracarda, C.5    Szczylik, C.6
  • 14
    • 30944452354 scopus 로고    scopus 로고
    • Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
    • Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23(31):7889-7896
    • (2005) J Clin Oncol , vol.23 , Issue.31 , pp. 7889-7896
    • Hainsworth, J.D.1    Sosman, J.A.2    Spigel, D.R.3    Edwards, D.L.4    Baughman, C.5    Greco, A.6
  • 16
    • 39149083925 scopus 로고    scopus 로고
    • A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
    • (June 20 Supplement)
    • Garcia JA, Rini BI, Mekhail T, Triozzi P, Elson C, Nemec C et al (2007) A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol, 2007 ASCO annual meeting proceedings part I, vol 25, no 18S (June 20 Supplement): 15586
    • (2007) J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I , vol.25 , Issue.18 S , pp. 15586
    • Garcia, J.A.1    Rini, B.I.2    Mekhail, T.3    Triozzi, P.4    Elson, C.5    Nemec, C.6
  • 18
    • 36749098248 scopus 로고    scopus 로고
    • Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
    • (June 20 Supplement)
    • Merchan JR, Liu G, Fitch T, Picus J, Qin R, Pitot HC et al. (2007) Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol, 2007 ASCO annual meeting proceedings part I, vol 25, no 18S (June 20 Supplement):5034
    • (2007) J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I , vol.25 , Issue.18 S , pp. 5034
    • Merchan, J.R.1    Liu, G.2    Fitch, T.3    Picus, J.4    Qin, R.5    Pitot, H.C.6
  • 19
    • 0032886302 scopus 로고    scopus 로고
    • MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
    • Uemura H, Nakagawa Y, Yoshida K, Saga S, Yoshikawa K, Hirao Y et al (1999) MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81(4):741-746
    • (1999) Br J Cancer , vol.81 , Issue.4 , pp. 741-746
    • Uemura, H.1    Nakagawa, Y.2    Yoshida, K.3    Saga, S.4    Yoshikawa, K.5    Hirao, Y.6
  • 22
    • 3342967945 scopus 로고    scopus 로고
    • Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma
    • Grabmaier K, de Weijert AMC, Verhaegh GW, Schalken JA, Oosterwijk E (2004) Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23(33):5624-5631
    • (2004) Oncogene , vol.23 , Issue.33 , pp. 5624-5631
    • Grabmaier, K.1    de Weijert, A.M.C.2    Verhaegh, G.W.3    Schalken, J.A.4    Oosterwijk, E.5
  • 23
    • 0027462558 scopus 로고
    • Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250
    • Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD et al (1993) Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol 11(4):738-750
    • (1993) J Clin Oncol , vol.11 , Issue.4 , pp. 738-750
    • Oosterwijk, E.1    Bander, N.H.2    Divgi, C.R.3    Welt, S.4    Wakka, J.C.5    Finn, R.D.6
  • 24
    • 0031724558 scopus 로고    scopus 로고
    • Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma
    • Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S et al (1998) Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4(11):2729-2739
    • (1998) Clin Cancer Res , vol.4 , Issue.11 , pp. 2729-2739
    • Divgi, C.R.1    Bander, N.H.2    Scott, A.M.3    O'Donoghue, J.A.4    Sgouros, G.5    Welt, S.6
  • 26
    • 0032694512 scopus 로고    scopus 로고
    • Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250
    • Steffens MG, Boerman OC, de Mulder PH, Oyen WJ, Buijs WC, Witjes JA et al (1999) Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 5(10 Suppl):3268s-3274s
    • (1999) Clin Cancer Res , vol.5 , Issue.10 SUPPL.
    • Steffens, M.G.1    Boerman, O.C.2    de Mulder, P.H.3    Oyen, W.J.4    Buijs, W.C.5    Witjes, J.A.6
  • 27
    • 4544260382 scopus 로고    scopus 로고
    • Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer
    • Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ et al (2004) Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45(8):1412-1421
    • (2004) J Nucl Med , vol.45 , Issue.8 , pp. 1412-1421
    • Divgi, C.R.1    O'Donoghue, J.A.2    Welt, S.3    O'Neel, J.4    Finn, R.5    Motzer, R.J.6
  • 28
    • 27244448455 scopus 로고    scopus 로고
    • Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma
    • Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C et al (2005) Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 23(27):6540-6548
    • (2005) J Clin Oncol , vol.23 , Issue.27 , pp. 6540-6548
    • Brouwers, A.H.1    Mulders, P.F.2    de Mulder, P.H.3    van den Broek, W.J.4    Buijs, W.C.5    Mala, C.6
  • 29
    • 1542399581 scopus 로고    scopus 로고
    • Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re
    • Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH et al (2004) Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45(2):327-337
    • (2004) J Nucl Med , vol.45 , Issue.2 , pp. 327-337
    • Brouwers, A.H.1    van Eerd, J.E.2    Frielink, C.3    Oosterwijk, E.4    Oyen, W.J.5    Corstens, F.H.6
  • 30
    • 0030017852 scopus 로고    scopus 로고
    • Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors
    • Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR et al (1996) Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19(3):184-191
    • (1996) J Immunother Emphasis Tumor Immunol , vol.19 , Issue.3 , pp. 184-191
    • Surfus, J.E.1    Hank, J.A.2    Oosterwijk, E.3    Welt, S.4    Lindstrom, M.J.5    Albertini, M.R.6
  • 31
    • 11144354471 scopus 로고    scopus 로고
    • A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
    • Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C et al (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90(5):985-990
    • (2004) Br J Cancer , vol.90 , Issue.5 , pp. 985-990
    • Bleumer, I.1    Knuth, A.2    Oosterwijk, E.3    Hofmann, R.4    Varga, Z.5    Lamers, C.6
  • 32
    • 29144503225 scopus 로고    scopus 로고
    • A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma
    • Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Voller MC, Melchior S, Warnaar SO et al (2006) A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 175(1):57-62
    • (2006) J Urol , vol.175 , Issue.1 , pp. 57-62
    • Bleumer, I.1    Oosterwijk, E.2    Oosterwijk-Wakka, J.C.3    Voller, M.C.4    Melchior, S.5    Warnaar, S.O.6
  • 33
    • 33947504376 scopus 로고    scopus 로고
    • Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial
    • Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S et al (2007) Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 8(4):304-310
    • (2007) Lancet Oncol , vol.8 , Issue.4 , pp. 304-310
    • Divgi, C.R.1    Pandit-Taskar, N.2    Jungbluth, A.A.3    Reuter, V.E.4    Gonen, M.5    Ruan, S.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.